Background Clostridium difficile infection (CDI) recurs in nearly one-third of patients who develop an initial infection. Recurrent CDI (RCDI) is associated with considerable morbidity, mortality, and cost. Treatment for RCDI has not been not well examined. Methods A systematic review. Results Sixty-four articles were identified evaluating eight different treatment approaches: metronidazole, vancomycin, fidaxomicin, nitazoxanide, rifampin, immunoglobulins, probiotics, and fecal bacteriotherapy. The metaanalysis found vancomycin to have a similar efficacy to metronidazole, although studies used varying doses and durations of therapy. Fidaxomicin was slightly more efficacious than vancomycin, though the number of studies was small. Good evidence for probiotics was limited. Fecal bacteriotherapy was found to be highly efficacious in a single randomized trial. Conclusion Metronidazole and vancomycin have good evidence for use in RCDI but heterogeneity in treatment duration and dose precludes robust conclusions. Fidaxomicin may have a role in treatment, but evidence is limited to subgroup analyses. Fecal bacteriotherapy was the most efficacious. Saccharomyces boulardii may have a role as adjunctive treatment.
Introduction
Clostridium difficile infection (CDI) is the leading cause of healthcare-associated infectious diarrhea in hospitalized patients and is on the rise in the outpatient setting [1] . Recent years have seen the emergence of a hyper-virulent strain, BI/NAP/27 [2] , associated with increased toxin production and adverse clinical outcomes [1, [3] [4] [5] [6] . Recurrent or relapsing CDI (RCDI) occurs in approximately 20-30 % of patients following initial CDI, and up to 45 % of patients will have subsequent recurrences [7] . The economic costs associated with RCDI are estimated to exceed $13,000 per relapse [8] .
Current Infectious Diseases Society of America (IDSA) guidelines [9] recommend discontinuation of the offending antibiotic and treatment with metronidazole (or vancomycin for severe CDI) for the first episode of CDI. The same options are recommended for the first recurrence. Subsequent episodes of RCDI are recommended to be treated by tapering or pulse-dosed vancomycin.
Effective treatments for RCDI are urgently needed; yet, few therapeutic options have been well studied. We undertook a systematic review to critically evaluate the efficacy of therapeutic interventions in RCDI.
Methods

Search strategy and data abstraction
With the aid of an expert librarian, MEDLINE, CINAHL, EMBASE, and the Cochrane Review Database were searched in September of 2012 for articles on RCDI treatment without publication date restrictions. The full search strategy is available in Supplemental Table 1 . Inclusion criteria for the review were human trials or reports that provided outcome data on a specific intervention for RCDI. No language restrictions were applied; abstracts and articles were translated as needed. The references of all relevant articles, including reviews and editorials, were manually inspected for potentially relevant studies. The search strategy was in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [10] .
Data abstracted from each study included the specifics of the treatment regimen, the definition of RCDI used, concomitant or adjunctive therapies, study design, inclusion and exclusion criteria, duration of surveillance, and study endpoint. Study endpoints that included clinical cure were considered stronger methodologically than those that used solely surrogates, such as the clearance of toxin from stool. Outcomes were measured as both clinical cure and recurrence. Clinical cure was defined as an initial positive response to therapy in a patient with RCDI. Recurrence was defined as a patient who, after initial response to RCDI therapy, had a subsequent relapse following clinical cure. When provided, side effect data and mortality data were abstracted as well.
When appropriate, quantitative analysis was performed with DerSimonian and Laird random effects modeling in RevMan software [11] .
Assessment of risk of bias
Two authors independently assessed the risk of study bias. Because retrospective, prospective, and interventional studies met the inclusion criteria, the risk of bias was assessed according to the instrument developed by Downs and Black [12] . This tool encompasses six sections which assess reporting, external validity, internal validity/bias, internal validity/confounding, and power. Inter-rater agreement was excellent (Cohen's j coefficient = 0.86). Disagreements were resolved by a third author. Studies with scores C12 were considered to be high-quality studies.
Results
Literature review
A total of 4,242 articles were retrieved with the search strategy described above. 173 additional studies were identified via manual chart review. Of these, 105 studies analyzing eight major treatments strategies for RCDI were identified and included in this review (see PRISMA diagram, Fig. 1 ).
Vancomycin
Ten studies evaluated the efficacy of vancomycin in RCDI, with four case series [13] [14] [15] [16] and six randomized controlled trials (RCTs) [17] [18] [19] [20] [21] [22] including 615 patients with 376 sustained responses to therapy (61 %). Initial cure rates ranged from 20 to 100 %, with sustained cure rates ranging between 49 and 100 %. Six studies were of high quality. Study endpoints were histologic resolution of pseudomembranous colitis (PMC) in one study [13] , resolution of toxin positive assay in one study [18] , and clinical resolution in the remaining studies.
One study was exclusively among inpatients [14] ; the remainder included both in-and outpatients. All studies were among adults. Variable dosing and administration methods were used; this is summarized in Table 1 .
Examining high-quality trials using vancomycin, three studied a metronidazole comparator [15] [16] [17] and two fidaxomicin [19, 20] . The metronidazole comparator studies included 179 patients given metronidazole compared to 310 receiving vancomycin. Using sustained response (e.g., no recurrence), vancomycin was as efficacious as metronidazole [relative risk (RR) 1.08, 95 % confidence interval (CI) 0.85-1.35, I 2 = 0 %, p = 0.53). Studies comparing fidaxomicin to vancomycin, discussed further below, included a total of 79 patients in each arm, and appeared slightly more efficacious than vancomycin (RR 1.86, 95 % CI 1.04-3.31, I 2 = 0 %, p = 0.04) (Fig. 2) . Pulsing or tapering doses of vancomycin has demonstrated efficacy in small studies and subgroups [13, 15] , and has been adopted as part of the current guidelines but has not yet been evaluated in large RCTs [7, 23] . Tapering vancomycin involves a prolonged regimen where the dose is slowly reduced over several weeks. Pulsing involves a dose of vancomycin every 3 days following the completion of a full 10-14-day course for several weeks [24] .
Evidence supporting the use of vancomycin is moderate. There is considerable variability in dosing and duration for RCDI, but it is currently the standard of care in treating RCDI.
Metronidazole
Two case series [15, 16] and three RCTs [17, 25, 26] evaluated metronidazole in RCDI. A total of 283 patients were treated with metronidazole-containing regimens, with a second recurrence in 86 patients (29 %). Rates of initial response were between 77 and 100 %. One study concluded that metronidazole was non-inferior to vancomycin in a first relapse [16] , while two favored vancomycin regimens [15, 17] . Two studies used metronidazole plus placebo as part of a control group to evaluate either C. difficile immune whey or probiotic regimens [25, 26] , discussed further below.
The dosing regimens and duration of metronidazole are summarized in Table 2 . The patient populations were exclusively adults. All studies included both inpatients and outpatients. Primary endpoints were resolution of symptoms without recurrence for 1 or 2 months [17, 26] or 1 year [15] .
Current IDSA guidelines endorse one repeat course of metronidazole as the standard of care for the first recurrence [9] . A temporal correlation of treatment failure has been noted since the emergence of the BI/NAP1/027 strain [7, 27] . It is not recommended beyond a first recurrence because of the risk of accumulation of neurotoxic metabolites [9] . All of the identified studies were of high quality, and found a fairly consistent efficacy, similar to vancomycin (see Fig. 2 ).
Other antibiotics
Several other antibiotics have been examined, particularly nitazoxanide [18, 28] , rifaximin [29] [30] [31] [32] [33] [34] [35] , and fidaxomicin [19, 20] . Nitazoxanide is a thiazoline-class antibiotic developed primarily as an anti-parasitic agent. Early studies in primary CDI indicated it to be relatively safe and well tolerated, with a response rate similar to metronidazole [36] . Two prospective studies [18, 28] on 47 patients found an initial response in 27 patients, with one second recurrence (55 % sustained response). Both studies were in adults, used a mix of in -and outpatients, and dosed the nitazoxanide at 500 mg twice daily for 10 [21] or 14 days [18] . One study used clinical resolution as an endpoint [21] , while the other used toxin assay negativity as the endpoint [18] . In each study, the authors noted efficacy rates that were similar to vancomycin in treating RCDI (see Supplemental Table 1) .
Seven publications report the use of rifaximin in treating RCDI, including two case reports [29, 30] , three case series [31] [32] [33] [34] , and one prospective trial [35] . These total 49 patients, and report an aggregate of 12 failures. One study used toxin clearance as the primary endpoint [35] , while the rest used clinical resolution. Three used rifaximin in combination with vancomycin regimens [30, 31, 33] (see Supplemental Table 2 ).
Fidaxomicin is a poorly absorbed, orally administered narrow-spectrum macrolide [37] . Both studies of fidaxomicin were prospective trials in a mixed inpatient-outpatient population [19, 20] , totaling 116 patients. Clinical resolution was the endpoint of both studies. Initial response rates were high at 93 %, with sustained response occurring in 82 % of patients. One study indicated a clear reduction in recurrence after treating primary CDI, and evaluated RCDI as a subset. In that secondary analysis, fidaxomicin was superior to vancomycin in preventing a second recurrence in 28 days [19] . Fidaxomicin is the only drug other than vancomycin approved by the U.S. Food and Drug Administration (FDA) for CDI [38] . Both of the existing studies on fidaxomicin compared the drug to vancomycin and found non-inferiority [19, 20] , with pooled results showing the slight superiority of vancomycin (see Fig. 2 ). However, it is worth noting that this medication is considerably more expensive than oral vancomycin, and may have decreased activity against the NAP1-027 strain [19] (see Table 3 ).
Treatment of recurrent Clostridium difficile infection 45 Alternative antibiotic regimens deserve study, but lack the records of vancomycin and metronidazole. Evidence for fidaxomicin is moderate in light of two positive, highquality studies. The current evidence for nitazoxanide and rifaximin is weak.
Immunoglobulins
Ten studies were found evaluating immunoglobulin treatments, with one evaluating oral immunoglobulins [25] , one monoclonal antibodies [39] , and the remainder polyclonal IVIG [40] [41] [42] [43] [44] . These articles included 77 patients, and had 21 relapses (26 %). No study reported an initial response rate lower than 80 %. One study used toxin clearance as the primary endpoint [39] , with the rest reporting clinical resolution. Two studies were determined to have a low risk of bias [25, 39] , while the remainder had a high risk of bias (see Table 4 ).
Depressed levels of IgG generally, and anti-C. difficile toxin A deficiency specifically, have been demonstrated as a risk factor for developing severe or recurrent CDI [45, 46] . In a previous systematic review, the greatest benefit was observed in studies restricted to known hypogammaglobulinemia patients [47] , but the overall study quality was low. A more recent, high-quality RCT evaluating a monoclonal antibody against C. difficile toxins demonstrated benefits in preventing recurrence in 29 patients with active RCDI refractory to vancomycin and/or metronidazole [39] .
The use of polyclonal IVIG in the treatment of recurrent or severe CDI has equivocal evidence. Evidence for using monoclonal IVIG is stronger, with a single RCT showing benefit [39] . While oral immune globulin (OIG) appears promising and has a good biological rationale for its efficacy, the solitary high-quality study to date did not demonstrate a benefit over metronidazole, which is considerably more cost-effective than the expensive immunoglobulin preparations.
Probiotics
Intestinal microbiota in a typical human outnumber host cells by 10:1, and are involved in a plethora of metabolic and biochemical interactions vital to immunologic function [48] . The complexity and activity of the flora has been likened to an organ [49] , and recent advances have found a limited number of ''enterotypes'', balanced microbiota, which are consistent with a state of health [50] . Antibioticassociated diarrhea (AAD), a condition in which the microbiota is severely disrupted, allows overgrowth by virulent bacteria such as C. difficile. Probiotics attempt to remedy this by providing normal host microbes to recolonize the colon and prevent invasion by pathogens. The majority of studies of probiotics in AAD have been preventive and have indicated some benefit [51] , while a growing number of studies have evaluated its utility in the treatment of CDI. Common probiotic formulations are derived from Lactobacillus spp., Enterococcus faecium, Bifidobacteria spp., and Saccharomyces boulardii.
Eight studies evaluated probiotics in RCDI, four using S. boulardii [17, [52] [53] [54] , three Lactobacillus spp. [26, 55, 56] , and one a non-toxigenic strain of C. difficile [57] (see Table 5 ). All studies used clinical symptoms as a primary endpoint. Three were considered to be high-quality studies [17, 26, 54] . In RCDI, S. boulardii has the strongest evidence, with two placebo-controlled RCTs finding benefit [17, 52] , though the first did not control for prior antibiotic regimens, and the second found benefit only when used as an adjunct to high-dose vancomycin [58] . A third trial noted a high relapse rate (66 %), though this study found higher concentrations of S. boulardii in stool correlated with a decreased risk of recurrence [53] .
Lactobacillus spp. have not been well evaluated, with two case series supporting the use of Lactobacillus GG and one randomized underpowered trial failing to show significant benefit from L. plantarum 299v [26] . Evidence for the use of other organisms is limited to case reports.
Overall, the evidence for the adjunctive use of S. boulardii in treating RCDI is moderate. Other probiotic formulations need to be studied for efficacy.
Fecal bacteriotherapy
Fecal bacteriotherapy (FBT) delivers a complete complement of intestinal microbiota and its milieu to restore normal ecology. FBT has been a reported treatment of PMC since 1958 [59] . Since then, dozens of retrospective studies have been published supporting its use. The major adverse effects associated with FBT in the published studies have been complications of the delivery mechanism, e.g., gastrointestinal bleeding from nasogastric tube placement [60] .
There is variability among published protocols, but all are largely consistent with a highly detailed FBT protocol published by Bakken et al. [60] . Potential donors are screened for bloodborne viruses and gastrointestinal illness. A stool sample from a donor is collected and mixed with milk, water, or saline, filtered, and diluted to a target volume which is delivered by nasogastric tube or enema, rectal tube, or colonoscope [60] . Success rates appear to be higher with lower gastrointestinal delivery, repeated treatments, and greater volume of infusate [61] , though a recent meta-analysis found no difference in upper versus lower gastrointestinal delivery [62] .
Thirty-three publications addressing FBT for RCDI were identified. There were two prospective trials [63, 64] , seven case reports [65] [66] [67] [68] [69] [70] [71] , 23 case series , and one RCT [22] . These included 609 patients and reported 63 failures (10.3 %). Except for one study using toxin clearance as a primary endpoint [77] , all used clinical criteria to define success (see Table 6 ).
An RCT undertaken in the Netherlands, the FECAL trial, demonstrated the superiority of fecal transplant delivered into the duodenum over vancomycin (RR 3.05, 95 % CI 1.09-290.05). Initial treatment cured 81 % of RCDI patients, and subsequent retreatment reached 94 % efficacy. However, it is worth noting that the treatment failure rate for vancomycin is considerably higher in this study than in any other study. This may be, in part, due to the long follow up interval of 10 weeks capturing more treatment failures. Although the total number in this trial was small (n = 16 in FBT treatment group), and the study excluded both critically ill and immunocompromised patients, this represents the strongest evidence to date in support of this practice [22] .
Discussion
The treatment options of RCDI are limited; yet, the impact on patients and healthcare costs is considerable [7] [8] [9] . In our systematic review, we found that most therapeutic options currently available for treatment of RCDI have, at best, moderate evidence to support their use. We found moderate-strength evidence that treatment with either oral vancomycin or oral metronidazole has consistent efficacy for clinical cure. One is not clearly more efficacious than the other. There is insufficient data regarding optimal dosing regimens, especially in critically ill patients. Pulsing or tapering doses of oral vancomycin have weak evidence, as does intracolonic vancomycin. No study evaluated intravenous metronidazole therapy for RCDI.
Among novel antibiotic approaches, fidaxomicin has been the most rigorously examined, mainly in primary CDI to evaluate recurrence. It is an option for RCDI, but parameters should be developed in order to guide appropriate use. Few studies have evaluated nitazoxanide, and evidence supporting the use of either is of low quality.
Non-antimicrobial options for the treatment of RCDI should be examined further. We found only one highquality study suggesting that S. boulardii could be useful as an adjunctive therapy with high-dose vancomycin.
Evidence for polyclonal intravenous immunoglobulins is weak in RCDI, though novel approaches with monoclonal immunoglobulins and oral immunoglobulins appear promising, and merit further study in the RCDI population.
FBT has a large body of non-comparative literature supporting its use, but, to date, has only been studied in one RCT. However, this does appear to be a promising option, and a recent review of 27 papers found an 89 % overall success rate, similar to our findings [61] .
The available data would suggest that a reasonable clinical approach for a patient with RCDI would be the removal, if possible, of triggering antibiotics, followed by: (1) second treatment with either metronidazole or vancomycin with consideration of adjuvant probiotics, (2) consideration of either fidaxomicin or alternative dosing regimens of vancomycin (pulse or taper) depending on cost factors, and then (3) FBT. Data supporting each measure in this algorithm become sequentially weaker, but all of these measures have reasonable evidence for efficacy, and could be attempted in a patient with RCDI.
Our analyses have several limitations, most stemming from the design of the included studies. Except for subgroups, we were not able to perform a rigorous metaanalysis of the efficacy of therapeutic options for RCDI because of the non-comparative nature of the studies and the clinical heterogeneity. Each treatment approach had a very limited number of studies, thus, even after pooling, the study populations remained quite small. Also, publication bias is a concern for interventions where case series predominate, as positive results are more likely to be published. Finally, we did not examine all possible reported interventions for RCDI treatment, mainly because of the very limited data. For example, two other interventions, colonic irrigation [95] and tigecycline [96] have been reported as being successful in single-case series, but there are inadequate data to evaluate these interventions. Other interventions that have shown some success in primary CDI, like tolevamer [97] and cholestyramine [98] , have not been evaluated specifically in RCDI.
The lack of data for the effective treatment of RCDI underscores the importance of prevention of primary CDI. Antimicrobial stewardship programs are important for the prevention of CDI [99, 100] and prompt discontinuation of offending antibiotics when CDI is detected may hasten recovery and reduce the risk of RCDI [101, 102] . Future studies should examine therapies specifically for RCDI using multisite, adequately powered, methodologically rigorous study designs.
